Research and Development (R&D) Expenses: R&D expense was $32.7 million for the first quarter of 2026, as compared to $19.6 ...

In the world of contemporary R&B, Kehlani has long been celebrated for a radical brand of transparency that mirrors the ...

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional ...

Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027LB-102 has potential to be the first benzamide approved ...

A Toronto woman with bipolar disorder is asking an Ontario court to grant her emergency access to medical assistance in dying ...

For over 50 years, the state’s politics was defined by a stable, deeply institutionalised bipolarity. TVK has upset that equation ...

News and commentary from the psychiatry world ...

Xenon Pharmaceuticals’ bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient ...

This Boston-based biotech innovator in CNS disorders just reported significant insider selling amid a year of standout stock ...

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in ...

Prosecutors argued that Anthony Ross hid a prior family and history of child abuse before killing wife and two children on ...